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systemic lupus erythematosus (SLE) induced by pristane in BALB/c mice. Lupus mice were established
by conﬁrming elevated levels of autoantibodies and IL-6 after intraperitoneal injection of pristane. Mice
were then treated with daily oral doses of SAA for 5 months in parallel with mice treated with prednisone
and aspirin as positive controls. The levels of autoantibodies were monitored at monthly intervals and
nephritic symptoms observed by hematoxylin and eosin (H&E) and periodic acid–Schiff (PAS) staining.
Western blot analysis of renal tissue was also employed. SAA treatment caused a signiﬁcant reduction in
the levels of anti-Sm autoantibodies and reduced renal histopathological changes and pathological effects.
SAA treatment also signiﬁcantly inhibited the phosphorylation of IKK, IκB and NFκB in renal tissues of
lupus mice. In conclusion, the results suggest that SAA alleviates renal injury in pristane-induced SLE in
BALB/c mice through inhibition of phosphorylation of IKK, IκB and NFκB.1
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Systemic lupus erythematosus (SLE) is a chronic autoimmune disease
characterized by the appearance of autoantibodies which react with
many organs and systems, including the skin, kidneys, heart, blood
vessels, and nervous system. The pathogenesis involves a complicated
interaction between genetic and environmental factors and the innate
and acquired immune systems1–3. Although survival of SLE patients
has improved remarkably over the last few decades, the accumulation
of disease- and therapy-related complications continues to place an
enormous economic burden on both patients and society4.
The course of SLE is not entirely clear with periods of ﬂares
interspersed with periods of less severe disease5. Renal damage is
one of the most common and serious consequences of SLE6 with
lupus nephritis causing signiﬁcant morbidity and mortality if left
untreated7. In fact, the Lupus Foundation of America4 has
established that morbidity in female patients exceeds 90%, most
of whom range in age from 15 to 45. Protecting the kidneys is
therefore an important factor in the pharmacotherapy of SLE.
As an animal model of SLE, pristane-injected mice broadly
simulate the clinical symptoms of the disease and have been used
to investigate the effects of potential pharmacotherapies. In 1984, a
depside of d-(þ)-β-(3,4-dihydroxyphenyl)-lactic acid and 2-(3,4-
dihydroxyphenylethenyl)-caffeic acid named salvianolic acid A
(SAA, Fig. 1), was isolated from the dried roots of Salvia
miltiorrhiza Bge.8. It was conﬁrmed to scavenge lipid free radicals
and inhibit lipid peroxidation as effectively as vitamin E9. More
importantly, it has been shown to protect the myocardium10,11,
blood vessels12,13 and injured hepatocytes14. Due to these multiple
pharmacological effects, we sought to evaluate its ability to
decrease the levels of serum autoantibodies and protect the kidneys
in lupus induced by pristane in BALB/c mice.2. Materials and methods
2.1. Animals
Sixty female BALB/c mice (age 2 months, weight 1872 g) were
obtained from Vital River Laboratories, Beijing, China. Theof Salvianolic acid A.
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and temperature and exposed to a 12-h/12-h light/dark cycle with
free access to puriﬁed water and a standard diet. All experimental
protocols in this study were approved by the Laboratories
Institutional Animal Care and Use Committee of the Chinese
Academy of Medical Science and Peking Union Medical College.
2.2. Materials
Materials [suppliers] were as follows: SAA (purity 98%) [Depart-
ment of Medicinal Chemistry, Institute of Materia Medica,
Chinese Academy of Medical Sciences and Peking Union Medical
College]; aspirin, 2,6,10,14-tetramethylpentadecane (pristane), calf
thymus DNA (dsDNA), histone H1 human antigen (histone) and
bovine serum albumin (BSA) [Sigma–Aldrich Co., St. Louis, MO,
USA]; prednisone [National Institutes for Food and Drug Control,
Beijing, China]; native bovine Sm antigen (Sm) [Raybiotech Inc.,
Norcross, GA, USA]; mouse IL-6 enzyme-linked immunosorbent
assay (ELISA) kit and mouse IgG total ELISA kits [Affymetrix
Ebioscience Inc., San Diego, CA, USA]; bicinchoninic acid kit for
protein determination [Applygen Technologies Inc., Beijing,
China]; antibodies against phosphorylated inhibitor of nuclear
factor kappa-B kinase (p-IKK), phosphorylated inhibitor of NFκB
(p-IκB) and phosphorylated nuclear factor κB (p-NFκB), GAPDH
and 3,3ʹ,5,5ʹ-tetramethylbenzidine (TMB) substrate [Cell Signaling
Technology Inc., Beverly, USA]; horse anti-mouse IgG (biotin
conjugate), goat anti-mouse IgM (biotin conjugate) and streptavi-
din (HRP conjugate) [Beijing Zhongshan Golden Bridge Biotech-
nology Co., Ltd., Beijing, China]. All other reagents were
analytical grade and used as received.
2.3. Experimental protocol
SAA, prednisone and aspirin were administered to animals as saline
solutions. A total of 60 female BALB/c mice were randomly
divided into ﬁve equal groups: control, model, SAA, prednisone and
aspirin (n¼12 per group). On the ﬁrst day, an intraperitoneal (i.p.)
injection of 0.5 mL normal saline (NS) was administered to the
control group, and an i.p. injection of 0.5 mL pristane (0.783 g/mL
at 20 1C) administered to all other groups. Mice in the control and
model groups were given NS each day by gavage while mice in the
SAA, prednisone and aspirin groups were administered SAA (5 mg/
kg/d), prednisone (5 mg/kg/d) and aspirin (300 mg/kg/d) by gavage.
The latter two groups served as positive controls. Blood samples
were collected from the tail vein before treatment (0) and 1, 2, 3, 4,
and 5 months after treatment and serum analysed for the levels of
autoantibodies. After collecting the last sample, all mice were
euthanized and kidneys removed for pathological examination and
Western blotting.
2.4. ELISA for autoantibodies
Anti-dsDNA, histone and Sm autoantibodies (IgG or IgM) were
investigated by ELISA as described recently15. ELISA platesal injury in systemic lupus erythematosus induced by pristane in BALB/c
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0.5 μg/mL Sm antigens were incubated overnight at 4 1C. The
following day, plates were washed with PBS–Tween-20 and
incubated with blocking buffer (PBS–2% BSA) for 2 h at 37 1C.
They were then incubated for 3 h at 25 1C with murine serum
diluted 1:2000, 1:200 and 1:400 after which plates were washed
again and incubated for 1 h at 37 1C with biotin-conjugatedhorse-
antimouse IgG or biotin-conjugatedgoat-antimouse IgM antibodies
diluted 1:1000 with 2% BSA. Subsequently, plates were washed
and incubated for 0.5 h at 37 1C with horseradish peroxidase–
labeled streptavidin diluted 1:1000 with 2% BSA. The plates were
then washed again and after adding 50 μL of substrate (TMB) to
the wells were maintained for 30 min at 25 1C. The reaction was
terminated by adding 50 μL 2 mol/L H2SO4 to each well and
absorbance read at 450 nm using a microplate reader. The mean
enzyme indices (EI) of the samples in the different groups were
calculated as:
EI %ð Þ ¼OD450 of samples=ðMean OD450 of control mice
þ3 SDÞ  100
2.5. ELISA analysis for IL-6 and total IgG
The concentrations of interleukin-6 (IL-6) and total IgG in the
supernatant of serum were measured using appropriate commercial
ELISA analysis for the murine form of IL-6 and total IgG,
according to manufacturer's instructions. The intensity of each
sample was read at 450 nm in a microplate spectrophotometer.
2.6. Histopathological analysis
Kidneys were ﬁxed for 24 h in 4% formalin prior to parafﬁn
embedding. Sections were stained with hematoxylin and eosin
(H&E) and periodic acid–Schiff (PAS) and then examined under aFigure 2 Peripheral blood was collected from BALB/c mice on day 30 a
(A) dsDNA-IgG; (B) dsDNA-IgM; (C) Sm-IgG; (D) Sm-IgM; (E) IL-6
*Po0.05, ***Po0.001 vs. the control group.
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glomerulonephritis, renal tubular lesions and interstitial inﬂammation.
2.7. Western blotting
Kidney tissue was homogenized in ice-cold RIPA cell lysis buffer
and, after centrifugation, soluble proteins were quantiﬁed using the
bicinchoninic acid (BCA) protein assay as described previously16.
Phosphorylated levels of IKK, IκB and NFκB were determined by
Western blotting after mixing with loading buffer and boiling
for 10 min. Bands were quantiﬁed by Quantity One software
(Bio-Rad, Richmond, CA, USA) and normalized to GAPDH as an
internal control.
2.8. Statistical analysis
Results are expressed as mean7SEM. The signiﬁcance of
differences between groups was determined by unpaired t test or
one-way ANOVA followed by Dunnett's multiple comparison test.
Po0.05 was regarded as statistically signiﬁcant. Figures in this
article are depicted using GraphPad Prism6 (GraphPad Software
Inc., La Jolla, CA, USA).3. Results
3.1. Pristane-induced lupus mice
To conﬁrm the establishment of pristane-induced lupus, serum
autoantibodies and IL-6 were measured by ELISA. On day 30, the
levels of anti-dsDNA, anti-Sm autoantibodies, IL-6, and total IgG
in pristane injected groups were notably higher than corresponding
levels in the control group (Fig. 2). Mice were considered positivefter intraperitoneal injection of pristane (þ) or NS (–) and the levels of
and (F) total IgG determined by ELISA. Values are means7SEM,
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Figure 3 Appearance of BALB/c mice on day 30 after intraperitoneal injection of pristane to the model group showing (A) depilation of facial hair;
(C) abdominal trichomadesis; (E) lipogranuloma in the peritoneal cavity. Appearance of BALB/c mice on day 30 after intraperitoneal injection of NS
to the control group showing (B) normal hair on the face; (D) normal hair on the abdomen; (F) the normal peritoneal cavity without foreign matter.
Yihuang Lin et al.4for lupus if EI4100% for anti-dsDNA and Sm autoantibodies
(IgG or IgM). Taking the concentrations of IL-6 and total IgG as
auxiliary reference, mice with EIo100% (including IgG and IgM)
were rejected. The lupus positive mice were randomly divided into
the model, SAA, prednisone and aspirin groups.
On day 15 after administration of pristane, depletion of facial
hair (Fig. 3A) and abdominal trichomadesis (Fig. 3C) were
observed in the model group, but not in the control group. Finally,
when mice were sacriﬁced, lipogranuloma (Fig. 3E) was observed
in the peritoneal cavity of the model group but not in the control
group (Fig. 3B, D and F).3.2. Serum autoantibody levels
SLE is characterized by a large and increasing array of auto-
antibodies to cellular constituents17. The levels of anti-dsDNA,
anti-histone and anti-Sm autoantibodies (IgG and IgM) in the
pristane-injected groups were all signiﬁcantly different from the
level in the control group. The concentration of total IgG was
clearly elevated at month 1 (Fig. 4).
The levels of anti-dsDNA IgG autoantibodies in pristane-
injected groups decreased at month 1, reached a peak at month
2 and then declined (Fig. 4A). The levels of anti-dsDNA IgM
autoantibodies decreased from the initial level and subsequently
remained at a low level. However, in the SAA group, levels of
anti-dsDNA IgG and IgM autoantibodies were not signiﬁcantly
different from those in the model group.
The levels of anti-histone IgG autoantibodies began to increase
in the pristane-injected groups, reached a peak at month 1 and then
declined (Fig. 4B) Anti-histone IgM levels also peaked at month
1 then decreased at month 2 before increasing slightly over
subsequent months. Statistical analysis showed that at monthsPlease cite this article as: Lin Yihuang, et al. Salvianolic acid A alleviates ren
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were signiﬁcantly lower than in the model group. The data also
show that SAA treatment decreased the level of anti-histone-IgM
autoantibodies after month 2.
The levels of anti-Sm IgG autoantibodies increased after admin-
istration of pristane, reached a peak at month 1, decreased until
month 3 and then increased again (Fig. 4C). The levels of anti-Sm
IgM autoantibodies decreased at month 1 and then increased until
reaching a plateau at month 3. The levels of anti-Sm IgG
autoantibodies in the SAA treated group were signiﬁcantly different
from those in the model group at months 1, 4 and 5 and levels of
anti-Sm IgM autoantibodies were clearly lower at months 2 and 5.
The data show that SAA treatment continued to reduce the levels of
anti-Sm IgG and IgM autoantibodies through to the last stage.
The concentrations of total IgG in pristane-injected groups were
increased at month 1 and reached a peak at month 4 (Fig. 4D). The
results showed that total IgG was obviously decreased by SAA
treatment at month 3 and reached its lowest level at month 4.3.3. Renal histopathology
As shown by H&E and PAS staining, pristane-induced lupus
resulted in immunocomplex-mediated glomerulonephritis. In the
control group, the size and cell counts of glomeruli were normal
and the glomerular capillary wall was thin (Fig. 5A and F).
Histologic sections from the model group exhibited severe renal
damage characterized by mesangial broadening and increasing cell
layers, glomerular atrophy with capillary dilation and thickening of
capillary walls (Fig. 5B), basement membrane thickening, mesangial
matrix expansion, and dilation of renal tubules (Fig. 5G). These renal
histopathological changes were diminished in the SAA treatment
group, particularly the glomerular lesions (Fig. 5C and H). Similarly,al injury in systemic lupus erythematosus induced by pristane in BALB/c
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Figure 4 SAA treatment reduces serum levels of (A) anti-dsDNA; (B) anti-histone and (C) anti-Sm autoantibodies, as well as (D) total IgG in
mice with pristane-induced lupus. Serum samples from mice were collected before treatment (0) and at 1, 2, 3, 4 and 5 months after treatment and
the levels of autoantibodies determined by ELISA based on optical density (OD) at 450 nm. Values are means7SEM from twelve independent
experiments. *Po0.05, **Po0.01, ***Po0.001 vs. control group; #Po0.05, ##Po0.01, ###Po0.001 vs. model group.
SAA alleviates renalinjury in SLE in BALB/c mice 5in both the prednisone and aspirin treated groups, renal pathological
changes were signiﬁcantly less (Fig. 5D–E and I–J).3.4. Phosphorylation of IKK, IκB and NFκB in kidney
Because SAA treatment provided good protection of kidney in
lupus mice, Western blot analysis was employed to determine
whether the protection was related to inhibition of the activation of
IKK (Fig. 6A), IκB (Fig. 6B) and NFκB (Fig. 6C) in renal tissues.Please cite this article as: Lin Yihuang, et al. Salvianolic acid A alleviates ren
mice. Acta Pharmaceutica Sinica B (2016), http://dx.doi.org/10.1016/j.apIn the model group, p-IKK, p-IκB, p-NFκB were clearly activated
in renal tissues but in the SAA-treated group, phosphorylation of
IKK, IκB and NFκB was signiﬁcantly inhibited compared with the
model group.4. Discussion and conclusions
There remain many questions relating to the aetiology and
pathophysiology of SLE. First, SLE is characterized by a varietyal injury in systemic lupus erythematosus induced by pristane in BALB/c
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Figure 5 Histology of kidney tissue collected at the time of euthanasia stained with (A–E) H&E and (F–J) PAS. (A) and (F) control group;
(B) and (G) model group; (C) and (H) SAA group; (D) and (I) prednisone group; (E) and (J) aspirin group.
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Figure 6 Chronic treatment with SAA suppresses the activation of the p-IKK, p-IκB, p-NFκB signaling pathways. Crude proteins obtained from
kidney tissues were analyzed by Western blotting using speciﬁc antibodies against (A) p-IKK; (B) p-IκB; and (C) p-NFκB. Quantitative analysis
was performed by densitometry using an internal control (GAPDH). Values are means7SEM from six independent experiments. **Po0.01 vs.
control group; #Po0.05, ##Po0.01, ###Po0.001 vs. model group.
SAA alleviates renalinjury in SLE in BALB/c mice 7of clinical manifestations and large increases in autoantibody
levels that have led some to argue that it shares pathogenic
mechanisms with a diverse range of diseases18,19. Secondly, the
pathogenesis of SLE is characterized by a broad range of
pathogenic events that likely reﬂect the heterogeneity of the
disease20. Thirdly, the immunomodulators aspirin, corticosteroids,
antimalarials and immunosuppressants have been the mainstay of
pharmacotherapy for SLE but, because of the complexity of the
disease and the side effects of drugs, treatment remains unsatis-
factory4,21. Due to this reason, it has been proposed that multiple
medications should be used to treat the disease and new
procedures are required3.
Pristane-treated mice develop clinical manifestations of SLE,
including arthritis, immune complex-mediated glomerulonephritis
and vasculitis, as well as increases in autoantibodies22,23. In this
study, we consistently observed depilation of facial hair, abdom-
inal trichomadesis and lipogranuloma in the model group and
noted the depilation displayed a similar manifestation to that
observed in SLE patients. Furthermore, we found increasing levels
of autoantibodies and renal lesions in pristane-injected mice that
comprehensively simulate clinical manifestations of the disease.
On this basis, we maintain we established a reliable and useful
animal model of SLE to investigate its pharmacotherapy.
SLE is associated with increased cardiovascular incidence and
fatality due to premature atherosclerosis that leads to the prophylactic
use of aspirin for the primary and secondary prevention of coronary
heart disease21. Oral corticosteroids, most commonly prednisone, are
the main therapeutic choice for SLE and to treat lupus nephritis
generally24,25. However, the current drugs for SLE suffer from major
reason side effects which limit their use25,26. In consideration of lack
of satisfactory clinical drug and their different use as two types of
anti-inﬂammatory drugs in treating SLE, mice treated with prednisone
and aspirin served as positive controls in the present study.
A rise in anti-Sm autoantibodies is well recognized as the most
speciﬁc feature of SLE and a criterion of the American College of
Rheumatology for the diagnosis of the disease27. We observed
SAA treatment caused a signiﬁcant reduction in the level of anti-
Sm autoantibodies including those of IgG and IgM and alsoPlease cite this article as: Lin Yihuang, et al. Salvianolic acid A alleviates ren
mice. Acta Pharmaceutica Sinica B (2016), http://dx.doi.org/10.1016/j.apreduced the levels of total IgG. Some studies have indicated an
association between anti-Sm autoantibodies and some particular
disease manifestations such as lupus nephritis27. Because these
positive effects of SAA treatment translated into improved renal
function and the attenuation of histological damage, we conducted
further experiments to elucidate the mechanism of renal protection
and found that SAA inhibited the levels of phosphorylation of
IKK, IκB and NFκB in renal tissues. Thus we maintain that SAA
plays a therapeutic role in SLE by blocking the IKK/IκB/NFκB-
mediated inﬂammatory response.
In conclusion, we have demonstrated that SAA plays a
protective role against the elevations in autoantibody levels and
renal lesions in a mouse model of SLE. Furthermore we have
shown that the renal protection is mediated by inhibiting the IKK/
IκB/NFκB signaling pathway. However, given that SAA exerts
multiple pharmacological effects, we anticipate it can alleviate
other debilitating symptoms of SLE and further research is needed
to conﬁrm if this is the case.Acknowledgments
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